GYRE earnings analysis
What we found in GYRE's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Gyre’s Q2 2026 revenue of $29.105 million improved 26.5% sequentially and 7.8% year over year, and exceeded consensus by 10.1%, but the $0.12 EPS loss was twice the expected $0.06 loss and worsened from the $0.10 loss in Q1. The supplied filing excerpt does not provide current gross margin, operating margin, free cash flow, segment results, or updated quantitative guidance. The most material newly disclosed risk is concentrated ownership and potential forced selling of shares pledged against GNI Japan’s JPY 20 billion loan.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Rebounded Sequentially
- Revenue was $29.105 million, up from $23 million in Q1 2026, a 26.5% sequential increase, and up from $27 million in Q2 2025, a 7.8% year-over-year increase. Revenue also exceeded the $26.44 million consensus estimate by 10.1%.
- Revenue Beat, EPS Missed
- Reported EPS was a loss of $0.12 versus a $0.06 consensus loss, representing a $0.06 miss and a 100% larger loss than estimated.
- Earnings Loss Worsened
- Reported EPS declined from a $0.10 loss in Q1 2026 to a $0.12 loss in Q2 2026, indicating sequential earnings deterioration despite the revenue recovery.
- Disclosure Controls Effective
- Management concluded that disclosure controls and procedures were effective as of June 30, 2026, providing reasonable assurance over required reporting.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Concentrated Ownership and Thin Float
- The company added a new risk that its common stock is thinly traded and ownership is concentrated. GNI Japan and its subsidiaries beneficially own a majority of outstanding shares, while the public trading float is limited, increasing the risk that substantial sales could cause a significant price decline.
- Pledged Shares Create Selling Risk
- GNI Japan disclosed a JPY 20 billion term loan secured by shares of Gyre held by the GNI Parties. The loan was funded on July 1, 2026, matures on July 1, 2027, and a default could lead to foreclosure and sale of pledged shares, potentially causing a change in control.
- Merger Integration Controls
- The company is evaluating the impact of the Merger on internal control over financial reporting. The transaction closed on May 4, 2026, and management stated that this evaluation could materially affect internal controls.
- Board Composition Changed
- The Board of Directors was reduced from 10 members to 9 following the July 18, 2026 death of director David M. Epstein, Ph.D., creating a governance and oversight change after the quarter end.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.12
What they said about what is next.
The provided 10-Q excerpt does not include a quantitative outlook. Prior annual revenue guidance was $100.5 million to $111 million, but current-period guidance status is not stated in the supplied filing text.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 8, 2026
- Gyre Therapeutics reported Q1 2026 revenues of $22.5 million, slightly up from $22.1 million in the prior year but below expectations. The company recorded a net loss of $9.9 million, a stark contrast to the $3.7…
- 10-K · March 13, 2026
- Gyre Therapeutics is a commercial-stage biopharma focused on antifibrotic small molecules with a China commercial franchise anchored by ETUARY® (pirfenidone) and an advancing liver-fibrosis pipeline led by Hydronidone.…
- 10-Q · November 7, 2025
- Gyre reported Q3 revenue of $30,564 (thousands) and diluted EPS of $0.03, with operating income of $6,925 (thousands) driving a 22.7% operating margin. Cash and cash equivalents increased to $40,402 (thousands)…
- 10-Q · August 11, 2025
- Gyre reported Q2 revenue of $26.8M, up $1.55M (6.1%) year-over-year and up $4.71M (21.4%) sequentially, while diluted EPS was $0.00. Gross margin remained high at 95.7% but operating margin compressed to 8.1% from…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing GYRE makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever